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Summary: Indications and treatment goals for SRS have changed since the publication of RTOG 
90-05. We present initial retrospective outcomes from a new dose selection algorithm in use at 
our institution felt to be more contemporary with doses being used in the radiosurgery community 
today and report our local control and toxicity outcomes. This dose selection algorithm will be 
subject to a forthcoming prospective phase 2 trial.
Introduction: To evaluate safety and efficacy of an institutional dose selection algorithm in the treatment of 
brain metastases (BM) with single fraction radio-surgery (SRS).
Methods and Materials: The medical records of 65 patients with ≤10 BM treated with GK at our 
institution between April 2012 and October 2012 were reviewed retrospectively. The prescription 
doses used in this study ranged from 16-22Gy and were based upon RTOG 90-05 guideline doses 
subsequently modified at our institution depending on lesion number, lesion volume, institutional 
experience and prior history of whole brain radiation therapy (WBRT). Primary endpoint was local 
recurrence (LR) with additional outcomes measured including distant intracranial recurrence (DIR), 
death without local recurrence (DWLR) and alive and disease free (ADF). Fine Gray competing risk 
analysis was used to examine factors affecting local recurrence.
Results: Median follow up was 8.9 months (range 1.0-29.6months) and 12 month overall 
survival was 37% (95% CI 24.9-49.1%). Overall local recurrence rate was 7.7%. On competing 
risks regression analysis, no variable was significantly associated with local recurrence, 
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1. INTRODUCTION
The incidence of brain metastases (BM) in 
patients with a metastatic cancer diagnosis has 
been estimated to be as high as 30-40% [1-4]. With 
advances in systemic therapy resulting in longer 
survival, the management of brain metastases has 
become increasingly important. Whole brain radia-
tion therapy (WBRT) remains a standard of care in 
the management of BM however it can be associ-
ated with an increased incidence of neurocognitive 
adverse effects.[5] Stereotactic radiosurgery (SRS) 
is therefore becoming an increasingly popular man-
agement option in these patients both as sole first 
line treatment as well as salvage treatment after ini-
tial SRS or WBRT. [6]
RTOG 90-05 determined maximum safe and 
tolerated doses for single fraction radiosurgery as 
salvage treatment for both recurrent previously irra-
diated primary brain tumors and brain metastases. 
[7] Recommended tolerated doses were defined by 
tumor diameter (marginal doses of 24, 18 and 15Gy 
for <20, 21-30 and 31-40 mm respectively) and these 
dosing guidelines are still commonly used today. 
Since the publication of the results of this trial over 
15 years ago however, the indications and goals for 
SRS in treatment of BM have changed significantly 
and it is possible that an updated standardization of 
these dosing guidelines may be more applicable in 
clinical practice today. We present initial safety and 
efficacy results of use of a dose selection algorithm 
developed within our institution from the original 
90-05 guidelines for single fraction radiosurgery in 
patients with BM treated with GK and scanned using 
a 1.5 Tesla MRI.
2. METHODS AND MATERIALS
The Medical Records for all patients undergoing SRS 
for BM at our institution treated with Gamma Knife radio-
surgery (GK) between April 2012 and October 2012 were 
reviewed. Patients with ≤ 10 brain metastases on GK-plan-
ning MRI were included for analysis. All GK patients at 
our institution were enrolled prospectively onto an Insti-
tutional Review Board approved Data Repository prior to 
treatment and informed consent or waiver of consent was 
obtained in all cases. Patients with extremely radiosensi-
tive tumor histologies (lymphoma, leukemia), evidence 
of leptomeningeal dissemination and resection of cranial 
metastases presenting for SRS cavity boost were excluded. 
Baseline demographics were recorded for all 
patients treated including age, gender, previous history 
of WBRT, number of lesions treated and performance 
status, previous SRS, tumor histology, tumor location 
and volume and previous intracranial surgery. 
2.1. Treatment 
All patients were treated using the Leksell Perfexion 
Gamma Knife (Elekta Medical Systems Inc, Atlanta, 
GA). Planning MRI scan was obtained on the morning 
of GK treatment following application of the stereo-
tactic head frame. Patients were scanned on a Siemens 
Magnetic Resonance Imaging Scanner. Double con-
trast gadolinium was administered in all cases unless 
the patient had significant renal dysfunction or con-
trast allergy and 1 mm slices were obtained for plan-
ning purposes. The images were transferred to Gamma 
Plan Software version 10.1 (Elekta Instruments, Atlanta 
GA) for the purposes of treatment planning. The plan-
including previous whole brain radiotherapy (WBRT), (SHR 1.21 [95%CI 0.13-11.5], p=0.87 and 
radioresistant versus radiosensitive histology (SHR 0.51 [95% CI 0.06-7.73], p=0.55). No patient 
developed grade 3 or higher neurotoxicity at 12 months following GK.
Conclusions: Initial local control and toxicity results from our institutional dose selection algorithm 
are reported here. Comparison of our results with RTOG 90-05 is difficult due to significant 
differences in the patient population and their treatments. The applicability of this algorithm 
merits further investigation across multiple centers for the purpose of treatment and clinical trial 
standardization in single fraction SRS and will be the subject of a forthcoming phase 2 prospective 
study within our own institution.
Keywords: brain metastases, dose selection, stereotactic radiosurgery, gamma knife
Abbreviations: SRS = stereotactic radiosurgery; BM = brain metastases; GK = Gamma Knife;  
WBRT = whole brain radiation therapy; LR = local recurrence; DIR = distant intra-cranial recurrence; 
DWLR = death without local recurrence; ADF = alive and disease free
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ning target volume (PTV) was defined as the contrast 
enhancing tumor volume on the T1 weighted post con-
trast MRI images and the PTV was the same volume 
as the gross tumor volume (GTV) i.e. no margin was 
added to GTV to form PTV.
2.2. Dose selection algorithm
The dose selection algorithm was created using an 
initial sub-stratification of the guidelines in RTOG 
90-05 (24 Gy for <4.5cc. 18Gy for 4.6-14.0 cc. and 
15 Gy for >14.0 cc.) then modified based on institu-
tional experience is - shown in Table 2. Critical criteria 
involved in prescription dose selection included tumor 
histology, use of prior WBRT, individual tumor volume 
and number of metastases to be treated (1-4 or 5-10).
Overall, doses were raised for smaller lesion volume, 
radioresistant pathology (including melanoma, sarcoma 
and renal cell carcinoma) and in those patients without 
prior WBRT in order to try to obtain maximal treatment 
benefit. Doses were lowered in larger volume lesions, 
patients with 5-10 metastases and previous WBRT in 
order to reduce toxicity.
For lesions <4.5cc we lowered the dose from 24Gy 
to 22 Gy as in our experience these doses are equiva-
lent. Lesions between 4.5 cc and 14.0cc would nor-
mally be treated with 18 Gy as per RTOG guidelines. 
For the purposes of our algorithm, we raised the dose 
and stratified by diameter to between 20 and 22 Gy. If 
a patient had previous WBRT then we reduced the dose 
by 2Gy. For lesions >14.0cc (normally treated to 15Gy 
in RTOG 90-05), our starting point was 18Gy for dose 
selection with a 2 Gy reduction in dose for previous 
WBRT. A 1Gy reduction in dose was applied for vol-
ume greater than 22.0cc.
Only lesions located within the brainstem or adjacent 
the optic apparatus were not treated based on the algo-
rithm as marginal prescription dose for these lesions does 
not exceed 18Gy and 8Gy respectively in our institution.
Table 1. Patient Demographics
n %
Gender Male 33 50.8
Female 32 49.2
Karnofsky Performance Status KPS >70 54 83.1
<70  9 13.8
unknown  2 3.1
Radiosensitive histology Breast 9 13.8
NSCLC 26 40.0
Colorectal 1 1.5
Other 6 9.2
Radioresistant histology Renal 6 9.2
Melanoma 15 23.1
Sarcoma 2 3.1
Number of metastases at treatment 1-4 47 72.3
5-10 18 27.7
WBRT prior to SRS Yes 12 18.5
No 53 81.5
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2.3. Outcome measures
Primary endpoint was local recurrence (LR) as 
evaluated by RECIST criteria i.e an increase in the 
size of the lesion of ≥ 20%. Outcomes were recorded 
as local recurrence (LR), death without local recur-
rence (DWLR), distant intra-cranial recurrence (DIR) 
and alive and disease free (ADF). Patients were cen-
sored at DWLR or when WBRT was used at the time 
of DIR. Neurological toxicity was measured using the 
RTOG radiation morbidity criteria (Table 3). Patients 
were evaluated both clinically and radiographically at 
6 weeks post Gamma Knife treatment and at 3 monthly 
intervals thereafter with an MRI scan at each of these 
time points. Treatment-related imaging changes (pos-
sible radiation necrosis)– were included within LR in 
order to avoid the need to histopathologically validate 
imaging findings.[8]
2.4. Physics
Information on planning matrices was recorded 
including lesion location, tumor volume, treatment 
volume and prescription dose along with isodose line. 
Where possible, we aimed for the lowest achievable 
conformity index (defined as prescription isodose vol-
Table 2. Dose selection algorithm accounting for treatment volume, number of metastases, tumor histology and 
prior WBRT.
Planning 
Treatment 
Volume
RTOG 
90-05
Number of 
Metastases
Radioresistant / 
Prior WBRT
Radioresistant /
No Prior WBRT
Radiosensitive / 
Prior WBRT
Radiosensitive 
/ No Prior 
WBRT
0-4.5 cc 24 Gy
1-4 22 Gy 22 Gy 22 Gy 22 Gy
5-10 20 Gy 20 Gy 20 Gy 20 Gy
4.6-7.0 cc 18 Gy
1-4 22 Gy 22 Gy 20 Gy 22 Gy
5-10 20 Gy 20 Gy 18 Gy 20 Gy
7.1-8.5 cc 18 Gy
1-4 20 Gy 20 Gy 20 Gy 20 Gy
5-10 18 Gy 20 Gy 18 Gy 18 Gy
8.6-11.0 cc 18 Gy
1-4 20 Gy 20 Gy 18 Gy 20 Gy
5-10 18Gy 18 Gy 18 Gy 18 Gy
11.1-14.0 cc 18 Gy
1-4 20 Gy 20 Gy 18 Gy 20 Gy
5-10 16 Gy 18 Gy 16 Gy 18 Gy
14.1-22.0 cc 15 Gy
1-4 18 Gy 18 Gy 16 Gy 18 Gy
5-10 16 Gy 16 Gy 16 Gy 16 Gy
22.1-34.0 cc 15 Gy
1-4 16 Gy 16 Gy 15 Gy 16 Gy
5-10 16 Gy 16 Gy 15 Gy 16 Gy
Table 3. RTOG scale for radiation related morbidity criteria
RTOG score Definition
0 No change
1 Fully functional status (i.e., able to work) with minor neurologic findings, no medication needed
2
Neurologic findings present sufficient to require home case/ nursing assistance may be required/ 
medications including steroids/anti-seizure agents may be required
3 Neurologic findings requiring hospitalization for initial management
4
Serious neurologic impairment which includes paralysis, coma or seizures>3 per week despite 
medication/hospitalization required
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ume divided by planning target volume) between 1.0 
and 2.0. The entire PTV volume was covered by the 
prescription isodose and the most common prescription 
isodose line was the 50% line. 
2.5. Statistical analysis
The goal for an acceptable lesion local control rate 
was 80% based on a local recurrence rate of 20% at 
1 year in the RTOG 90-05 trial. Fine-Gray competing-
risks analysis accounting for age, gender, number of 
metastases treated (1-4 vs. 5-10), tumor histology (radi-
oresistant versus radio-sensitive), and prior WBRT was 
performed to examine factors affecting local control 
taking into account the competing risk of death. Time to 
endpoint was calculated from the day of Gamma Knife 
treatment.
3. RESULTS
3.1. Patient characteristics
A total of 65 consecutive patients were treated 
for 1-10 BM at our institution between April 2012 
and October 2012 were eligible for analysis. 53% 
of the patients were male and 47% were female 
(Table 1). Median age was 64 years (range 38 - 86 
years). Primary pathology included NSCLC 40.0% 
(n=26), melanoma 23.1% (n=15) and breast 13.8% 
(n=9). At the time of analysis, 41% of patients were 
alive. 12 (18.5%) patients had WBRT prior to SRS 
and the median interval between WBRT and SRS in 
these patients was 11.3 months (range 2.2 to 67.5 
months).
The single largest indication for GK (62.5%) was for 
prophylactic treatment of patients with new asympto-
matic BM found on routine screening or surveillance 
imaging. Presenting symptoms in the remaining 40% of 
patients included a mix of headache, seizure, gait insta-
bility, weakness / clumsiness, mental status changes, 
and cranial nerve palsy – often in combination. (36% 
(n=23) of patients had single metastases at time of GK, 
30% (n=19) had 2-4 metastases and 34% (n=22) had 
5-10 metastases at time of radiosurgery. 
3.2. Lesion characteristics
 A total of 236 lesions were treated. Lesion character-
istics are shown in Table 4. The most common location 
of metastases was in the frontal lobe (35.8%) 93.2% of 
lesions were less than 20mm in diameter, 5.9% were 
20-30mm in diameter and 0.9% 30-40mm. 89.1% of 
lesions were ≤4.5cc in volume (equivalent to spheri-
cal diameter of 2.04 cm). 5.0% of lesions were treated 
to the 40-49% isodose surface, 56.2% to the 50-59% 
isodose, 29.3% to the 60-65% isodose and 9.5% to the 
70% or greater isodose surface.
3.3. Outcome
Median follow up was 8.9 months (range 1.0-29.6 
months). 6 month overall survival was 64% (95% CI 
51-75%) and 12 month overall survival was 37% (95% 
CI 25-49%). 35.9% of patients (n=23) died without local 
recurrence (DWLR) and 12.5% (n=8) were alive and dis-
ease free (ADF) at last follow up. Freedom from LR+DIR 
analyzed by patient at 12 months was 31.0% (95% CI 
17.1-46.4%). Of the 236 lesions treated, there were no 
local failures at 6 months and only 4 (1.7%) local lesional 
failures at 12 months. Fine Gray competing risk regression 
analysis was used to estimate of a patient’s 12 month local 
recurrence-free survival (taking into account the compet-
ing risk of death) was 84.7% (95%CI 64.0-94.0%). 
The results of a Fine Gray regression analysis with 
regards to local control are shown in Figures 1a and 1b 
and Table 5. No variable was significantly associated 
with local control, including treatment volume and 5-10 
metastases (vs. 1-4) (SHR 6.11 [95% CI 0.64-58.8], 
p=0.12). There was no significant difference in compet-
ing risk analysis with regards to radioresistant versus 
radiosensitive histology (figure 1a), (SHR 0.51 [95% CI 
0.06-7.73], p=0.55). 
3.4. Local recurrence
The actuarial incidence of local recurrence and/or 
radionecrosis (lesions which could have met the crite-
ria for local recurrence due to an increase in size post 
treatment but which may have been due to radionecrosis 
rather than local treatment failure were included in the 
LR category) at 12 months was 6.2% and overall at time 
of analysis was 7.7%. All of the lesions which recurred 
were less than 2.0cm in diameter. Of the 5 patients who 
developed local recurrence, LR occurred at 8 months 
post GK in 2 patients. Both opted for palliative care 
rather than further active management. The third patient 
developed LR at 13 months post GK and was treated 
with WBRT. She was therefore censored at this time. 
This was a patient with a history of breast cancer with 
multiple treatments with GK for recurrent CNS disease. 
She is currently alive 29 months post WBRT. The fourth 
patient with a history of breast cancer underwent surgi-
cal resection of a progressive lesion 10 months post GK. 
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Histology was predominantly consistent primarily with 
radiation necrosis although a small focus of adenocar-
cinoma was found in one specimen. The patient subse-
quently progressed extra-cranially and died 3 months 
post-surgery/ 13 months post GK. The fifth patient devel-
oped slowly progressive LR at 10 months post GK which 
subsequently stabilized. At current follow up 24 months 
post GK, no salvage treatment has been required in this 
case and the patient remains alive and well.
No patient developed grade 3 or higher neurotox-
icity at 6 or 12 months following GK nor did any 
patient develop seizures or require surgery post GK 
for toxicity.
4. DISCUSSION
The landmark RTOG 90-05 study published in 2000, 
established safe and tolerable doses for single fraction 
radiosurgery (SRS) of both recurrent primary brain tumors 
and brain metastases (BM) following standard fractionated 
external beam radiation. [7] This study was conducted as a 
dose escalation trial with the primary aim of keeping CNS 
toxicity following SRS at less than 20%. 
Since the publication of RTOG 90-05, however, SRS 
has gained increasing popularity as a treatment for BM. 
Advances in systemic therapy, including the use of many 
new targeted and immune-based therapies in cancers 
such as melanoma and NSCLC [9,10,11], have resulted 
not only in an increasing number of patients diagnosed 
with brain metastases, but also more patients who are 
living longer after treatment of their brain metastases. 
This has resulted directly in an increased adoption of 
the use of SRS for post-WBRT salvage therapy [7] and 
emphasized the need to use an SRS treatment dose that 
is likely to ensure long-term control of treated lesions 
with a minimal risk of toxicity.
In addition, the indications for SRS in treatment of 
brain metastases since the publication of RTOG 90-05 
have changed significantly. The recognition of the need for 
regular screening and surveillance of the brain using higher 
resolution MRI [12, 13,14] in patients with systemic metas-
tases has resulted in an increasing number of small, asymp-
tomatic brain lesions being detected. Most of these patients 
are neurologically asymptomatic and given the superiority 
of SRS in local lesional control as well as the possibility 
of developing delayed neurocognitive side effects following 
WBRT, there has been a shift away from first-line WBRT 
for treatment of BM [6]. Indeed many radiosurgeons today 
Table 4. Lesion characteristics
n %
Lesion location Frontal 83 35.2
 Temporal 33 14.0
Parietal 30 12.7
Occipital 35 14.8
Cerebellar 39 16.5
Other 16 6.8
Lesion diameter <20mm 220 93.2%
20-30mm 14 5.9%
30-40mm 2  0.9%
Lesion volume 0-4.5 cc 223 94.5
4.6-7.0 cc 8 3.4
7.1-8.5 cc 1 0.4
8.6-11.0 cc 1 0.4
11.1-14.0 cc 1 0.4
14.1-22.0 cc 1 0.4
22.1-34.0 cc 1 0.4
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Figure 1
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would advocate first-line treatment with SRS alone for high 
functioning patients with 5-10 brain metastases [15,16]. 
Dosing guidelines for the use of SRS without prior WBRT 
have never been published. Accounting for all these factors 
raises the question as to whether a new dose selection cri-
teria refining the parameters laid down in RTOG 90-05 is 
needed in the modern era of SRS.
Based on our own institutional practice, it was observed 
that despite the standard RTOG 90-05 guideline doses of 
15, 18 and 24Gy, radiosurgeons at our institution would 
often prescribe modified doses in between these numbers 
i.e. 16, 20 and 22Gy taking into account lesion size and 
number to be treated (as an estimate of survival), histo-
pathology and history of previous WBRT. In order to 
standardize our practice and so as to allow us to compare 
outcomes and toxicities, we developed a dose selection 
algorithm based predominantly on a combination of the 
experience of our most senior radiosurgeons and past SRS 
cases given our previously published reports of compara-
ble outcomes to national standards. The application of the 
algorithm was initiated in April 2012 and remains in effect 
at our institution today. The goal of this retrospective study 
was then primarily to demonstrate safety and efficacy of 
this standardized dose algorithm for SRS and to establish 
that the algorithm could be implemented without signifi-
cant reduction in local or distant control. 
Kaplan Meier estimate of a patient’s 12 month lesional 
recurrence free survival was 81.4% which compares very 
favorably to the 1 year actuarial incidence of local pro-
gression in RTOG 90-05 of 48%. The two patient popu-
lations however are far from equivalent. RTOG 90-05’s 
schema permitted only single lesions to be targeted (either 
isolated lesions or dominant lesions in patients with mul-
tiple lesions) whereas only a third (32%) of the patients in 
our study had single metastases. The RTOG 90-05 study 
also allowed for CT based planning which would likely 
increase the irradiated volume and may impact the local 
control and radionecrosis rate when compared to the high 
resolution MRI used in our study. Patients with both pri-
mary glial tumors and brain metastases were included 
in RTOG 90-05 which would significantly impact the 
reported local control rate and all patients received re-irra-
diation of a previously treated lesion – some to doses as 
high as 60Gy in the original treatment region which would 
increase the likelihood of radiation necrosis. This contrasts 
sharply with the indications for radiosurgical treatment in 
this study where all patients undergoing SRS had brain 
metastases and 81.0% were radiation treatment naïve. 
Lastly, a comparison of the volumes treated between the 
2 studies also highlights differences between the treatment 
populations. In the RTOG 90-05 study 25.6% (40 out of 
156) of the lesions had diameters of <20mm compared 
with this study where 93.2% of the lesions were <20mm 
diameter. The significant differences in patient population 
between RTOG 90-05 and our study only highlights again 
the need to revisit dosing guidelines specific for brain 
metastases.
 In RTOG 90-05, surgical resection was encouraged 
for suspicious radiographic changes of RN and the rate 
of RN was found to be 11% at 2 years. Radiation necro-
sis is notoriously difficult to diagnose and to differentiate 
from tumor progression radiographically. Estimates of the 
incidence of RN vary from anywhere between 7 to 24% 
[17,18] and this is increasing as patients survive longer fol-
lowing SRS for BM and undergo more intensive post treat-
ment surveillance imaging. Several studies have shown a 
dose related correlation with RN including Kjellberg and 
Abe [19] who created a dose versus volume model that 
was thought to predict risk of radiation necrosis. The pos-
sibility of radiation necrosis was not specifically addressed 
in this study given its short follow-up period as these cases 
were included in our definition of local failure. Even if all 
cases of local recurrence in this study were in fact radia-
tion necrosis, an overall rate of 7.7% would be acceptable 
in comparison with rates reported in RTOG 90-05. The 
impact of our dose selection algorithm on rates of radia-
tion necrosis will be examined further in our prospective 
phase 2 study which will have 2 year follow-up data.
Limited data exists following the publication of 
RTOG 90-05 on the optimal SRS dose for brain metas-
tases. To our knowledge, in the only large study looking 
specifically at this topic, Shehata et al. [20] examined 
the optimal SRS dose for 468 patients with brain metas-
tases < 2cm in diameter and the influence of WBRT 
on local control. The authors concluded that WBRT 
was the single most influential factor in local lesional 
Table 5. results of competing risk analysis for local control
Hazard ratio 95% CI p value
Radioresistant (vs. radiosensitive) 0.51 0.06-7.73  0.55
1-4 ( vs. 5-9) 6.11 0.64-58.8 0.12
WBRT (vs. no WBRT) 1.21 0.13-11.5 0.87
Male Gender (vs. female) 1.0 0.15-7.0 0.97
Age (continuous variable) 0.98 0.84-1.15 0.83
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control and that WBRT + SRS doses of 20 Gy resulted 
in 99% lesional control versus 91% if doses less than 
20Gy were used. No improvement in local control but 
rather an increase in treatment related toxicity was seen 
in doses higher than 20Gy administered after WBRT. 
Of note in this study, only 17.5% of patients received 
WBRT prior to GK and the use of WBRT was not found 
to contribute to improved local control or increased 
toxicity.
This study was completed in anticipation of our pro-
spective phase 2 trial using the same algorithm as we 
switch to 3 Tesla MR imaging for SRS planning. Given 
the initial promising results, we hope ultimately, follow-
ing completion of this phase 2 study, to establish our dose 
selection algorithm for possible wider multi-institutional 
adoption as a framework for standardizing SRS dosing in 
the modern era of brain metastases management.
A major limitation of our retrospective analysis 
was the short follow up period and smaller patient 
numbers; we will present 2 year follow up data in our 
prospective trial. Also, since the analysis was retro-
spective, not all cases of radiosurgery performed at 
our institution used the rationalized dosing and it is 
possible that this could introduce significant bias in 
outcome data. Lastly, the created algorithm has been 
formulated based upon experience of local radiosur-
geons at our institution and as such therefore subject 
to institutional practice biases. While we hope to 
address these limitations and gather further toxicity 
data in our forthcoming prospective phase 2 protocol, 
we also recognize that multi-institutional validation of 
our results will also be required.
5. CONCLUSIONS 
Initial good local control and toxicity results from 
our institutional dose selection algorithm for radio-
surgical treatment of up to 10 brain metastases are 
reported. The results are difficult to compare to those 
reported in RTOG 90-05 given the significant differ-
ences in treatment population emphasizing the need 
for brain metastasis specific radiosurgery dose guide-
lines. The applicability of this algorithm merits fur-
ther investigation in a multi-institutional setting for 
the purpose of treatment and clinical trial standardiza-
tion in single fraction SRS and will be the subject of a 
forthcoming phase 2 prospective study within our own 
institution.
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